Transposon said its oral small molecule TPN-101 has been selected for testing as part of the HEALEY ALS platform trial.

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

Sustained tuberculosis infection rates among adolescents were not lower following BCG revaccination vs placebo.

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also helped maintain red blood cell levels at acceptable levels, reduced ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

- The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving ...